Log in to your Inderes Free account to see all free content on this page.

Scandion Oncology

Less than 1K followers

All

Webcasts

Press releases

3rd party

ShowingAll content types

Regulatory press release6/25/2025, 3:00 PM

Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025

Scandion Oncology

Regulatory press release6/25/2025, 12:00 PM

Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market

Scandion Oncology

Regulatory press release3/27/2025, 3:00 PM

Scandion Oncology Announces Results of Annual General Meeting

Scandion Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release3/12/2025, 12:10 PM

Scandion Oncology – Notice convening the Annual General Meeting

Scandion Oncology

Regulatory press release3/12/2025, 12:05 PM

Scandion Oncology - Annual Report 2024

Scandion Oncology

Regulatory press release3/12/2025, 12:00 PM

Scandion Oncology – Q4 & yearend report 2024

Scandion Oncology

Regulatory press release2/26/2025, 5:40 PM

Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks

Scandion Oncology

Regulatory press release2/26/2025, 5:35 PM

Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report

Scandion Oncology

Regulatory press release2/26/2025, 5:30 PM

Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting

Scandion Oncology

Regulatory press release1/13/2025, 6:00 AM

Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology

Regulatory press release11/20/2024, 4:30 PM

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Scandion Oncology

Regulatory press release11/14/2024, 7:30 AM

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology

Press release11/12/2024, 4:54 PM

Redeye: Scandion Oncology Q3 2024 - Searching for a partner

Scandion Oncology

Scandion Oncology, Audiocast with teleconference, Q3'24

Webcast11/11/2024, 8:00 AM

Scandion Oncology, Audiocast with teleconference, Q3'24

Scandion Oncology

Regulatory press release11/11/2024, 6:00 AM

Scandion Oncology – Interim Report Q3 2024

Scandion Oncology

Press release11/5/2024, 4:00 PM

Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology

Regulatory press release11/4/2024, 7:30 AM

Scandion Oncology announces the start of the exercise period for warrants of series TO 2

Scandion Oncology

Regulatory press release10/31/2024, 7:30 AM

Correction: Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Regulatory press release10/30/2024, 4:00 PM

Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Press release8/29/2024, 10:26 AM

Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope

Scandion Oncology

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.